Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44129   clinical trials with a EudraCT protocol, of which   7323   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin®

    Summary
    EudraCT number
    		 2008-001674-32
    Trial protocol
    		 FI  
    Global end of trial date
    31 Dec 2016

    Results information
    Results version number
    		 v1(current)
    This version publication date
    16 Feb 2018
    First version publication date
    16 Feb 2018
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    GHLIQUID-3676
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT00960128
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Novo Nordisk A/S
    Sponsor organisation address
    Novo Allé, Bagsvaerd, Denmark, 2880
    Public contact
    Clinical Reporting Anchor and Disclosure, Novo Nordisk A/S, clinicaltrials@novonordisk.com
    Scientific contact
    Clinical Reporting Anchor and Disclosure, Novo Nordisk A/S, clinicaltrials@novonordisk.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    15 Jan 2018
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    31 Dec 2016
    Global end of trial reached?
    Yes
    Global end of trial date
    31 Dec 2016
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To collect the post-marketing data on effectiveness and safety of real-life treatment with Norditropin.
    Protection of trial subjects
    The study was carried out in accordance with the Declaration of Helsinki. The study reference documents were submitted for notification/approval to IEC/IRB and, if locally required, for notification/approval to regulatory authorities and data privacy agencies.
    Background therapy
    		 Not applicable
    Evidence for comparator
    		 Not applicable
    Actual start date of recruitment
    01 Apr 2006
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Belgium: 33
    Country: Number of subjects enrolled
    Czech Republic: 1341
    Country: Number of subjects enrolled
    Denmark: 1186
    Country: Number of subjects enrolled
    Finland: 211
    Country: Number of subjects enrolled
    France: 3803
    Country: Number of subjects enrolled
    Germany: 7927
    Country: Number of subjects enrolled
    Hungary: 111
    Country: Number of subjects enrolled
    Ireland: 41
    Country: Number of subjects enrolled
    Israel: 152
    Country: Number of subjects enrolled
    Italy: 158
    Country: Number of subjects enrolled
    Lithuania: 108
    Country: Number of subjects enrolled
    Luxembourg: 2
    Country: Number of subjects enrolled
    Montenegro: 85
    Country: Number of subjects enrolled
    Netherlands: 153
    Country: Number of subjects enrolled
    Norway: 312
    Country: Number of subjects enrolled
    Russian Federation: 159
    Country: Number of subjects enrolled
    Serbia: 1373
    Country: Number of subjects enrolled
    Slovenia: 282
    Country: Number of subjects enrolled
    Spain: 6
    Country: Number of subjects enrolled
    Sweden: 1381
    Country: Number of subjects enrolled
    Switzerland: 534
    Country: Number of subjects enrolled
    United Kingdom: 866
    Worldwide total number of subjects
    20224
    EEA total number of subjects
    17921
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    40
    Infants and toddlers (28 days-23 months)
    557
    Children (2-11 years)
    12691
    Adolescents (12-17 years)
    4443
    Adults (18-64 years)
    2204
    From 65 to 84 years
    288
    85 years and over
    1

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 The study included 469 clinics from 23 countries: Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Lithuania, Luxembourg, Montenegro, Netherlands, Norway, Russian Federation, Saudi Arabia, Serbia, Slovenia, Spain, Sweden, Switzerland, United Kingdom

    Pre-assignment
    Screening details
    		 This was an international, multi-centre, observational study based on all clinical data registered in NordiNet® as part of normal clinical practice. Patients were included in the study if they were treated with Norditropin® according to routine clinical practice.

    Period 1
    Period 1 title
    Overall study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Not applicable
    Blinding used
    		 Not blinded

    Arms
    Arm title
    		 Norditropin®
    Arm description
    		 The study population comprised children and adults treated with Norditropin® in the course of normal clinical practice. The overall study period was from 01 Apr 2006 to 31 Dec 2016.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Somatropin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Somatropin as per routine clinical practice.

    Number of subjects in period 1
    		Norditropin®
    Started
    20224
    Completed
    12938
    Not completed
    7286
         Included in FAS but Excluded from EAS
    7286

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Norditropin®
    Reporting group description
    		 The study population comprised children and adults treated with Norditropin® in the course of normal clinical practice. The overall study period was from 01 Apr 2006 to 31 Dec 2016.

    Reporting group values
    		 Norditropin® Total
    Number of subjects
    		 20224 20224
    Age Categorical
    Units: Subjects
        In utero
    		 0 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0 0
        Newborns (0-27 days)
    		 40 40
        Infants and toddlers (28 days-23 months)
    		 557 557
        Children (2-11 years)
    		 12691 12691
        Adolescents (12-17 years)
    		 4443 4443
        Adults (18-64 years)
    		 2204 2204
        From 65-84 years
    		 288 288
        85 years and over
    		 1 1
    Gender Categorical
    Units: Subjects
        Female
    		 8678 8678
        Male
    		 11546 11546
    Subject analysis sets

    Subject analysis set title
    Growth Hormone Deficiency (GHD) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with Growth Hormone Deficiency who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Small for Gestational Age (SGA) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with Small for Gestational Age (SGA) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Turner Syndrome (TS) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with Turner Syndrome (TS) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Chronic Renal Disease (CRD) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with chronic renal disease (CRD) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Idiopathic Short Stature (ISS) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with idiopathic short stature (ISS) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Noonan Syndrome (NS) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with Noonan Syndrome (NS) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Prader-Willi Syndrome (PWS) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with Prader-Willi Syndrome (PWS) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Adult patients with adult growth hormone deficiency (AGHD) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis sets values
    		 Growth Hormone Deficiency (GHD) - Paediatric Population Small for Gestational Age (SGA) - Paediatric Population Turner Syndrome (TS) - Paediatric Population Chronic Renal Disease (CRD) - Paediatric Population Idiopathic Short Stature (ISS) - Paediatric Population Noonan Syndrome (NS) - Paediatric Population Prader-Willi Syndrome (PWS) - Paediatric Population Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Number of subjects
    7141
    3200
    936
    200
    317
    106
    67
    971
    Age Categorical
    Units: Subjects
        In utero
        Preterm newborn infants (gestational age < 37 wks)
        Newborns (0-27 days)
        Infants and toddlers (28 days-23 months)
        Children (2-11 years)
        Adolescents (12-17 years)
        Adults (18-64 years)
        From 65-84 years
        85 years and over
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    Gender Categorical
    Units: Subjects
        Female
    2460
    1463
    936
    75
    136
    30
    28
    434
        Male
    4681
    1737
    0
    125
    181
    76
    39
    537

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Norditropin®
    Reporting group description
    		 The study population comprised children and adults treated with Norditropin® in the course of normal clinical practice. The overall study period was from 01 Apr 2006 to 31 Dec 2016.

    Subject analysis set title
    Growth Hormone Deficiency (GHD) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with Growth Hormone Deficiency who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Small for Gestational Age (SGA) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with Small for Gestational Age (SGA) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Turner Syndrome (TS) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with Turner Syndrome (TS) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Chronic Renal Disease (CRD) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with chronic renal disease (CRD) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Idiopathic Short Stature (ISS) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with idiopathic short stature (ISS) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Noonan Syndrome (NS) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with Noonan Syndrome (NS) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Prader-Willi Syndrome (PWS) - Paediatric Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Paediatric patients with Prader-Willi Syndrome (PWS) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Subject analysis set title
    Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Adult patients with adult growth hormone deficiency (AGHD) who were being treated with Norditropin®. The population represents effectiveness analysis set.

    Primary: Change from baseline in Height Standard Deviation Scores (SDS) - Paediatric population

    		 Close Top of page
    End point title
    		 Change from baseline in Height Standard Deviation Scores (SDS) - Paediatric population [1]
    End point description
    Height standard deviation scores were calculated as per national standard. Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints.
    End point type
    Primary
    End point timeframe
    Up to 10 Years of follow up
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This was an observational, non-interventional study. Only descriptive statistics was performed.
    End point values
    		 Growth Hormone Deficiency (GHD) - Paediatric Population Small for Gestational Age (SGA) - Paediatric Population Turner Syndrome (TS) - Paediatric Population Chronic Renal Disease (CRD) - Paediatric Population Idiopathic Short Stature (ISS) - Paediatric Population Noonan Syndrome (NS) - Paediatric Population Prader-Willi Syndrome (PWS) - Paediatric Population
    Number of subjects analysed
    7141
    3200
    936
    200
    317
    106
    67
    Units: Standard Deviation Scores
    arithmetic mean (standard deviation)
        Baseline (n=7141,3200,936,200,317,106,67)
    -2.55 ± 1.10
    -2.97 ± 0.91
    -2.66 ± 0.93
    -2.74 ± 1.17
    -2.82 ± 0.99
    -2.83 ± 1.13
    -1.94 ± 1.48
        Year 1 Follow Up (n=5173,2231,725,136,245,70,43)
    0.69 ± 0.56
    0.65 ± 0.44
    0.54 ± 0.36
    0.61 ± 1.19
    0.52 ± 0.38
    0.51 ± 0.38
    0.85 ± 0.9
        Year 2 Follow Up (n=4403,1882,642,94,190,56,30)
    1.09 ± 0.75
    1.01 ± 0.57
    0.81 ± 0.52
    0.9 ± 0.76
    0.89 ± 0.59
    0.83 ± 0.64
    1.19 ± 1.13
        Year 3 Follow Up (n=3574,1538,540,69,139,40,28)
    1.36 ± 0.85
    1.29 ± 0.65
    0.99 ± 0.61
    1.14 ± 0.97
    1.09 ± 0.7
    1.01 ± 0.69
    1.23 ± 1.05
        Year 4 Follow Up (n=2683,1195,429,44,94,37,25)
    1.56 ± 0.95
    1.46 ± 0.69
    1.04 ± 0.66
    1.21 ± 1.14
    1.28 ± 0.74
    1.07 ± 0.7
    1.34 ± 1.22
        Year 5 Follow Up (n=1916,897,344,31,65,25,17)
    1.72 ± 1.05
    1.64 ± 0.71
    1.12 ± 0.67
    1.6 ± 1.07
    1.43 ± 0.81
    1.18 ± 0.82
    1.43 ± 1.26
        Year 6 Follow Up (n=1388,644,249,22,40,16,12)
    1.87 ± 1.11
    1.8 ± 0.77
    1.16 ± 0.65
    1.92 ± 1.13
    1.71 ± 0.85
    0.99 ± 0.75
    1.9 ± 1.01
        Year 7 Follow Up (n=941,447,184,14,28,10,11)
    2.03 ± 1.15
    1.94 ± 0.79
    1.07 ± 0.69
    1.95 ± 1.17
    1.86 ± 0.99
    0.93 ± 1.03
    1.26 ± 1.07
        Year 8 Follow Up (n=648,280,135,14,18,7,10)
    2.21 ± 1.21
    2.04 ± 0.77
    0.98 ± 0.68
    2.14 ± 1.07
    1.7 ± 0.68
    1.29 ± 1.02
    1.16 ± 1.06
        Year 9 Follow Up (n=456,186,85,9,9,7,7)
    2.26 ± 1.25
    2.01 ± 0.76
    0.88 ± 0.6
    2.54 ± 1.08
    1.74 ± 0.82
    1.05 ± 0.8
    1.63 ± 1.36
        Year 10 Follow Up (n=273,96,47,7,9,4,6)
    2.41 ± 1.35
    1.93 ± 0.89
    0.77 ± 0.78
    2.8 ± 0.74
    1.28 ± 0.96
    1.21 ± 0.51
    1.8 ± 1.25
    No statistical analyses for this end point

    Primary: Change from baseline in waist circumference - Adult population

    		 Close Top of page
    End point title
    		 Change from baseline in waist circumference - Adult population [2]
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints.
    End point type
    Primary
    End point timeframe
    Up to 10 years of follow up
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This was an observational, non-interventional study. Only descriptive statistics was performed.
    End point values
    		 Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Number of subjects analysed
    971
    Units: cm
    arithmetic mean (standard deviation)
        Female: Baseline (n=241)
    95.76 ± 15.77
        Female: Year 1 follow-up (n=130)
    -1.32 ± 5.29
        Female: Year 2 follow-up (n=93)
    -0.33 ± 6.88
        Female: Year 3 follow-up (n=64)
    0.68 ± 7.36
        Female: Year 4 follow-up (n=55)
    -0.2 ± 8.32
        Female: Year 5 follow-up (n=47)
    -0.51 ± 7.92
        Female: Year 6 follow-up (n=38)
    -0.33 ± 9
        Female: Year 7 follow-up (n=34)
    -1.94 ± 9.03
        Female: Year 8 follow-up (n=24)
    1.04 ± 10.93
        Female: Year 9 follow-up (n=20)
    1.1 ± 12.39
        Female: Year 10 follow-up (n=16)
    1.47 ± 10.66
        Male: Baseline (n=290)
    102.29 ± 13.21
        Male: Year 1 follow-up (n=124)
    -0.76 ± 6.56
        Male: Year 2 follow-up (n=104)
    -1.41 ± 5.94
        Male: Year 3 follow-up (n=71)
    -0.12 ± 6.43
        Male: Year 4 follow-up (n=63)
    0.1 ± 7.15
        Male: Year 5 follow-up (n=50)
    -0.24 ± 7.32
        Male: Year 6 follow-up (n=35)
    1.2 ± 5.95
        Male: Year 7 follow-up (n=31)
    -0.18 ± 6.88
        Male: Year 8 follow-up (n=31)
    2 ± 8.24
        Male: Year 9 follow-up (n=19)
    -2.74 ± 11.89
        Male: Year 10 follow-up (n=19)
    -0.37 ± 7.4
    No statistical analyses for this end point

    Secondary: Change from baseline in body weight - Adult population

    		 Close Top of page
    End point title
    		 Change from baseline in body weight - Adult population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Number of subjects analysed
    971
    Units: kg
    arithmetic mean (standard deviation)
        Female: Year 1 follow-up (n=269)
    -0.19 ± 8.3
        Female: Year 2 follow-up (n=206)
    1.46 ± 13.3
        Female: Year 3 follow-up (n=166)
    1.51 ± 11.26
        Female: Year 4 follow-up (n=134)
    1.05 ± 7.85
        Female: Year 5 follow-up (n=112)
    0.32 ± 7.51
        Female: Year 6 follow-up (n=97)
    0.67 ± 13.47
        Female: Year 7 follow-up (n=82)
    0.5 ± 8.2
        Female: Year 8 follow-up (n=63)
    0.27 ± 14.47
        Female: Year 9 follow-up (n=56)
    0.94 ± 8.37
        Female: Year 10 follow-up (n=42)
    -3.38 ± 22.32
        Male: Year 1 follow-up (n=311)
    0.45 ± 10.69
        Male: Year 2 follow-up (n=262)
    0.23 ± 6.66
        Male: Year 3 follow-up (n=193)
    1.27 ± 14.18
        Male: Year 4 follow-up (n=177)
    1.06 ± 10.04
        Male: Year 5 follow-up (n=139)
    0.79 ± 10.53
        Male: Year 6 follow-up (n=120)
    1.56 ± 9.10
        Male: Year 7 follow-up (n=94)
    0.88 ± 10.41
        Male: Year 8 follow-up (n=90)
    0.03 ± 16.37
        Male: Year 9 follow-up (n=66)
    -2.39 ± 23.42
        Male: Year 10 follow-up (n=52)
    -1.14 ± 22.36
    No statistical analyses for this end point

    Secondary: Change from baseline in weight SDS - Paediatric population

    		 Close Top of page
    End point title
    		 Change from baseline in weight SDS - Paediatric population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints. The number "9999.999" represents data not applicable for a particular arm.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Growth Hormone Deficiency (GHD) - Paediatric Population Small for Gestational Age (SGA) - Paediatric Population Turner Syndrome (TS) - Paediatric Population Chronic Renal Disease (CRD) - Paediatric Population Idiopathic Short Stature (ISS) - Paediatric Population Noonan Syndrome (NS) - Paediatric Population Prader-Willi Syndrome (PWS) - Paediatric Population
    Number of subjects analysed
    7141
    3200
    936
    200
    317
    106
    67
    Units: standard deviation scores
    arithmetic mean (standard deviation)
        Year 1 follow-up (n=2452,1114,386,46,117,42,25)
    0.44 ± 0.62
    0.54 ± 0.53
    0.32 ± 0.49
    0.45 ± 0.64
    0.31 ± 0.57
    0.25 ± 0.38
    0.79 ± 0.96
        Year 2 follow-up (n=2008,912,335,29,86,32,18)
    0.82 ± 0.86
    0.87 ± 0.69
    0.64 ± 0.64
    0.72 ± 0.7
    0.69 ± 0.72
    0.6 ± 0.65
    1.3 ± 1.51
        Year 3 follow-up (n=1508,694,270,22,63,24,17)
    1.08 ± 1.02
    1.12 ± 0.8
    0.85 ± 0.76
    1.14 ± 0.83
    0.86 ± 0.87
    0.75 ± 0.78
    1.52 ± 1.76
        Year 4 follow-up (n=1066,510,207,12,37,17,13)
    1.24 ± 1.12
    1.28 ± 0.91
    1.01 ± 0.83
    1 ± 0.9
    0.93 ± 0.88
    0.74 ± 0.73
    2.21 ± 1.79
        Year 5 follow-up (n=733,364,162,6,25,10,7)
    1.46 ± 1.26
    1.42 ± 0.92
    1.1 ± 0.82
    1.04 ± 1.11
    1.07 ± 0.92
    0.97 ± 0.83
    1.68 ± 1.56
        Year 6 follow-up (n=492,256,125,6,15,6,5)
    1.58 ± 1.37
    1.59 ± 0.88
    1.33 ± 0.89
    1.34 ± 1.41
    1.65 ± 1.21
    0.6 ± 0.76
    2.71 ± 1.71
        Year 7 follow-up (n=323,174,88,3,7,3,6)
    1.67 ± 1.49
    1.78 ± 1.06
    1.39 ± 0.91
    1.13 ± 1.45
    1.68 ± 0.91
    0.85 ± 1.19
    1.67 ± 1.7
        Year 8 follow-up (n=234,100,71,3,7,1,7)
    1.79 ± 1.66
    1.99 ± 1.03
    1.47 ± 0.92
    1.59 ± 1.33
    1.66 ± 1.84
    1.6 ± 99999.9999
    1.28 ± 1.73
        Year 9 follow-up (n=160,66,42,2,1,2,4)
    1.86 ± 1.39
    2.07 ± 0.93
    1.54 ± 0.86
    1.43 ± 2.16
    1.68 ± 99999.9999
    1.4 ± 0.34
    1.75 ± 2.38
        Year 10 follow-up (n=95,34,28,1,3,2,3)
    2.07 ± 1.29
    2.05 ± 1.06
    1.44 ± 0.82
    2.75 ± 99999.9999
    1.11 ± 2.03
    1.32 ± 0.34
    2.27 ± 2.89
    No statistical analyses for this end point

    Secondary: Change from baseline in HbA1c - Paediatric population

    		 Close Top of page
    End point title
    		 Change from baseline in HbA1c - Paediatric population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints. The number "9999.999" represents data not applicable for a particular arm.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Growth Hormone Deficiency (GHD) - Paediatric Population Small for Gestational Age (SGA) - Paediatric Population Turner Syndrome (TS) - Paediatric Population Chronic Renal Disease (CRD) - Paediatric Population Idiopathic Short Stature (ISS) - Paediatric Population Noonan Syndrome (NS) - Paediatric Population Prader-Willi Syndrome (PWS) - Paediatric Population
    Number of subjects analysed
    7141
    3200
    936
    200
    317
    106
    67
    Units: percentage of HbA1c
    arithmetic mean (standard deviation)
        Year 1 follow-up (n=734,411,149,18,39,10,5)
    0.04 ± 0.47
    0.05 ± 0.46
    0.1 ± 0.51
    0.36 ± 1.28
    0.02 ± 0.37
    0.15 ± 0.4
    0.1 ± 1.07
        Year 2 follow-up (n=583,309,119,15,29,8,4)
    0.06 ± 0.49
    0.02 ± 0.53
    0.09 ± 0.54
    0.22 ± 0.45
    0.09 ± 0.42
    0.24 ± 0.45
    -0.47 ± 0.84
        Year 3 follow-up (n=444,235,110,9,22,4,2)
    0.04 ± 0.49
    0.05 ± 0.57
    0.05 ± 0.66
    -0.17 ± 0.77
    0.06 ± 0.51
    -0.1 ± 0
    0.6 ± 0.57
        Year 4 follow-up (n=308,169,77,5,10,1,0)
    -0 ± 0.52
    0.05 ± 0.65
    -0.01 ± 0.56
    0.19 ± 0.75
    -0.02 ± 0.41
    -0.1 ± 99999.999
    99999.999 ± 99999.999
        Year 5 follow-up (n=196,126,66,3,6,1,1)
    -0.05 ± 0.57
    0.14 ± 0.45
    0.04 ± 0.6
    0.3 ± 0
    0.05 ± 0.15
    0 ± 99999.999
    0.4 ± 99999.999
        Year 6 follow-up (n=134,91,41,3,2,0,0)
    0.02 ± 0.51
    0.08 ± 0.43
    0.08 ± 0.68
    0.5 ± 0.56
    0.35 ± 0.49
    99999.999 ± 99999.999
    99999.999 ± 99999.999
        Year 7 follow-up (n=77,71,29,1,1,1,0)
    0.01 ± 0.7
    0.07 ± 0.49
    0.06 ± 0.65
    0 ± 99999.999
    0 ± 99999.999
    0.6 ± 99999.999
    99999.999 ± 99999.999
        Year 8 follow-up (n=54,47,18,2,3,1,0)
    0.08 ± 0.43
    0.12 ± 0.42
    0.22 ± 0.54
    0.1 ± 0.28
    -0.6 ± 0.85
    0.5 ± 99999.999
    99999.999 ± 99999.999
        Year 9 follow-up (n=34,33,9,1,0,1,0)
    0.11 ± 0.41
    -0.04 ± 0.34
    1.3 ± 2.87
    -0.3 ± 99999.999
    99999.999 ± 99999.999
    0.3 ± 99999.999
    99999.999 ± 99999.999
        Year 10 follow-up (n=13,15,4,1,0,1,0)
    0.21 ± 0.33
    -0.04 ± 0.33
    -0.05 ± 0.62
    0.1 ± 99999.999
    99999.999 ± 99999.999
    0.3 ± 99999.999
    99999.999 ± 99999.999
    No statistical analyses for this end point

    Secondary: Change from baseline in fasting blood glucose - Paediatric population

    		 Close Top of page
    End point title
    		 Change from baseline in fasting blood glucose - Paediatric population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints. The number "9999.999" represents data not applicable for a particular arm.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Growth Hormone Deficiency (GHD) - Paediatric Population Small for Gestational Age (SGA) - Paediatric Population Turner Syndrome (TS) - Paediatric Population Chronic Renal Disease (CRD) - Paediatric Population Idiopathic Short Stature (ISS) - Paediatric Population Noonan Syndrome (NS) - Paediatric Population Prader-Willi Syndrome (PWS) - Paediatric Population
    Number of subjects analysed
    7141
    3200
    936
    200
    317
    106
    67
    Units: mmol/l
    arithmetic mean (standard deviation)
        Year 1 follow-up (n=466,261,75,13,17,2,3)
    0.33 ± 0.95
    0.21 ± 1.04
    0.26 ± 0.76
    0.44 ± 0.89
    0.22 ± 0.9
    -0.87 ± 1.23
    -0.17 ± 0.47
        Year 2 follow-up (n=325,168,74,7,12,2,0)
    0.3 ± 1.01
    0.34 ± 1.03
    0.41 ± 0.79
    0.44 ± 0.51
    0.6 ± 0.71
    0.62 ± 0.16
    9999.999 ± 9999.999
        Year 3 follow-up (n=209,117,45,7,5,2,4)
    0.35 ± 1.26
    0.47 ± 1.3
    0.75 ± 1.69
    0.31 ± 0.52
    0.21 ± 1.75
    0.71 ± 0.28
    -0.27 ± 0.3
        Year 4 follow-up (n=152,79,40,4,1,0,0)
    0.3 ± 1.23
    0.52 ± 1.37
    0.51 ± 0.63
    0.43 ± 1.49
    0 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 5 follow-up (n=99,59,28,2,1,0,0)
    0.49 ± 1.12
    -0.18 ± 5.38
    0.46 ± 1.13
    0.95 ± 0.93
    0.1 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 6 follow-up (n=90,41,24,3,0,0,0)
    0.32 ± 1.05
    0.06 ± 0.91
    0.38 ± 0.96
    0.96 ± 0.81
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 7 follow-up (n=75,22,23,1,0,0,0)
    0.52 ± 1.03
    0.41 ± 0.76
    0.47 ± 0.96
    1.33 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 8 follow-up (n=60,12,11,2,0,0,0)
    0.7 ± 1.18
    0.31 ± 0.54
    0.48 ± 1.6
    0.8 ± 0.04
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 9 follow-up (n=39,7,6,1,0,0,0)
    0.55 ± 1.15
    0.05 ± 0.83
    0.44 ± 0.89
    1.17 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 10 follow-up (n=21,1,1,1,0,0,0)
    0.5 ± 1.3
    0.44 ± 9999.999
    0.39 ± 9999.999
    1 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    No statistical analyses for this end point

    Secondary: Change from baseline in total cholesterol - Paediatric population

    		 Close Top of page
    End point title
    		 Change from baseline in total cholesterol - Paediatric population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints. The number "9999.999" represents data not applicable for a particular arm.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Growth Hormone Deficiency (GHD) - Paediatric Population Small for Gestational Age (SGA) - Paediatric Population Turner Syndrome (TS) - Paediatric Population Chronic Renal Disease (CRD) - Paediatric Population Idiopathic Short Stature (ISS) - Paediatric Population Noonan Syndrome (NS) - Paediatric Population Prader-Willi Syndrome (PWS) - Paediatric Population
    Number of subjects analysed
    7141
    3200
    936
    200
    317
    106
    67
    Units: mmol/l
    arithmetic mean (standard deviation)
        Year 1 follow-up (n=443,193,69,19,18,7,0)
    -0.14 ± 0.73
    -0.06 ± 0.61
    -0.24 ± 0.58
    -0.45 ± 0.86
    -0.04 ± 0.62
    -0.46 ± 0.69
    9999.999 ± 9999.999
        Year 2 follow-up (n=314,124,48,12,14,3,0)
    -0.27 ± 0.82
    -0.23 ± 0.65
    -0.15 ± 0.72
    -0.87 ± 0.75
    -0.09 ± 1.08
    -0.89 ± 0.75
    9999.999 ± 9999.999
        Year 3 follow-up (n=202,67,31,7,6,3,3)
    -0.39 ± 0.9
    -0.12 ± 0.63
    -0.13 ± 0.9
    -0.84 ± 0.84
    0.47 ± 0.97
    -1.5 ± 1.42
    -0.16 ± 0.73
        Year 4 follow-up (n=143,60,24,6,2,2,0)
    -0.39 ± 0.94
    -0.24 ± 0.64
    0.01 ± 0.88
    -0.28 ± 0.51
    0.3 ± 0.57
    -1.35 ± 0.49
    9999.999 ± 9999.999
        Year 5 follow-up (n=87,49,12,3,1,1,0)
    -0.35 ± 0.75
    -0.23 ± 0.75
    -0.1 ± 0.71
    -0.63 ± 0.24
    -0.2 ± 9999.999
    -1.13 ± 9999.999
    9999.999 ± 9999.999
        Year 6 follow-up (n=79,38,10,2,0,1,0)
    -0.16 ± 0.75
    -0.27 ± 0.79
    0.25 ± 0.69
    -1 ± 0.68
    9999.999 ± 9999.999
    -0.77 ± 9999.999
    9999.999 ± 9999.999
        Year 7 follow-up (n=63,20,7,2,0,0,0)
    -0.3 ± 1.13
    -0.34 ± 0.63
    0.7 ± 0.93
    -3.74 ± 3.79
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 8 follow-up (n=48,18,5,2,0,0,0)
    -0.19 ± 0.67
    -0.33 ± 0.71
    -0.23 ± 1.25
    -4.13 ± 3.35
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 9 follow-up (n=26,20,2,1,0,0,0)
    -0.39 ± 0.88
    -0.27 ± 0.68
    0.11 ± 1.29
    -1.14 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 10 follow-up (n=12,8,1,1,0,1,0)
    -0.19 ± 0.8
    -0.15 ± 0.46
    0.88 ± 9999.999
    -2.14 ± 9999.999
    9999.999 ± 9999.999
    -1.38 ± 9999.999
    9999.999 ± 9999.999
    No statistical analyses for this end point

    Secondary: Change from baseline in HDL cholesterol - Paediatric population

    		 Close Top of page
    End point title
    		 Change from baseline in HDL cholesterol - Paediatric population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints. The number "9999.999" represents data not applicable for a particular arm.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Growth Hormone Deficiency (GHD) - Paediatric Population Small for Gestational Age (SGA) - Paediatric Population Turner Syndrome (TS) - Paediatric Population Chronic Renal Disease (CRD) - Paediatric Population Idiopathic Short Stature (ISS) - Paediatric Population Noonan Syndrome (NS) - Paediatric Population Prader-Willi Syndrome (PWS) - Paediatric Population
    Number of subjects analysed
    7141
    3200
    936
    200
    317
    106
    67
    Units: mmol/l
    arithmetic mean (standard deviation)
        Year 1 follow-up (n=233,110,30,6,5,3,0)
    -0.06 ± 0.44
    0.04 ± 0.34
    0 ± 0.35
    -0.04 ± 0.12
    -0.01 ± 0.16
    -0.03 ± 0.27
    9999.999 ± 9999.999
        Year 2 follow-up (n=168,64,19,4,6,2,0)
    -0.06 ± 0.34
    -0.04 ± 0.51
    0.07 ± 0.41
    -0.04 ± 0.42
    -0.01 ± 0.38
    -0.09 ± 0.13
    9999.999 ± 9999.999
        Year 3 follow-up (n=106,34,13,3,3,0,3)
    -0.12 ± 0.36
    0.02 ± 0.35
    0.02 ± 0.21
    0.08 ± 0.55
    0.05 ± 0.13
    9999.999 ± 9999.999
    0.06 ± 0.22
        Year 4 follow-up (n=65,37,9,3,2,0,0)
    -0.13 ± 0.41
    -0.06 ± 0.66
    0.21 ± 0.37
    0 ± 0.49
    0.03 ± 0.1
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 5 follow-up (n=31,25,4,1,1,0,0)
    -0.04 ± 0.31
    0.04 ± 0.37
    0.2 ± 0.57
    -0.34 ± 9999.999
    -0.42 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 6 follow-up (n=29,20,2,1,0,0,0)
    0.01 ± 0.34
    0.05 ± 0.46
    0.43 ± 0.05
    -0.28 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 7 follow-up (n=24,13,3,1,0,0,0)
    -0.09 ± 0.98
    -0.04 ± 0.32
    0.04 ± 0.12
    -0.08 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 8 follow-up (n=18,13,1,1,0,0,0)
    -0.31 ± 0.8
    0.29 ± 0.89
    0.13 ± 9999.999
    -0.05 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 9 follow-up (n=8,13,1,0,0,0,0)
    -0.43 ± 1.16
    -0.05 ± 0.21
    0.18 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 10 follow-up (n=2,6,0,0,0,0,0)
    0.26 ± 0.99
    0.67 ± 0.68
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    No statistical analyses for this end point

    Secondary: Change from baseline in LDL cholesterol - Paediatric population

    		 Close Top of page
    End point title
    		 Change from baseline in LDL cholesterol - Paediatric population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints. The number "9999.999" represents data not applicable for a particular arm.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Growth Hormone Deficiency (GHD) - Paediatric Population Small for Gestational Age (SGA) - Paediatric Population Turner Syndrome (TS) - Paediatric Population Chronic Renal Disease (CRD) - Paediatric Population Idiopathic Short Stature (ISS) - Paediatric Population Noonan Syndrome (NS) - Paediatric Population Prader-Willi Syndrome (PWS) - Paediatric Population
    Number of subjects analysed
    7141
    3200
    936
    200
    317
    106
    67
    Units: mmol/l
    arithmetic mean (standard deviation)
        Year 1 follow-up (n=218,105,30,5,5,3,0)
    -0.22 ± 0.73
    -0.08 ± 0.65
    -0.27 ± 0.52
    -0.4 ± 0.37
    -0.58 ± 1.86
    -0.03 ± 0.23
    9999.999 ± 9999.999
        Year 2 follow-up (n=151,60,18,3,6,2,0)
    -0.26 ± 0.64
    -0.17 ± 0.58
    -0.06 ± 0.65
    -1.86 ± 1.55
    0.02 ± 2.14
    -0.9 ± 0.57
    9999.999 ± 9999.999
        Year 3 follow-up (n=95,30,13,3,3,0,3)
    -0.41 ± 0.79
    -0.28 ± 0.44
    -0.41 ± 0.88
    -0.28 ± 1.14
    1.18 ± 1.03
    9999.999 ± 9999.999
    -0.15 ± 0.44
        Year 4 follow-up (n=59,34,9,3,2,0,0)
    -0.46 ± 0.8
    -0.26 ± 0.71
    0.15 ± 0.79
    -0.48 ± 0.48
    0.7 ± 1.13
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 5 follow-up (n=30,25,4,1,1,0,0)
    -0.4 ± 0.62
    -0.4 ± 0.6
    -0.69 ± 0.72
    -0.96 ± 9999.999
    0 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 6 follow-up (n=30,19,3,1,0,0,0)
    -0.35 ± 0.76
    -0.26 ± 0.49
    -0.53 ± 0.82
    -1.5 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 7 follow-up (n=24,12,4,1,0,0,0)
    -0.36 ± 0.95
    -0.32 ± 0.57
    -0.32 ± 1.13
    -5.98 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 8 follow-up (n=17,11,2,1,0,0,0)
    -0.51 ± 0.57
    -0.2 ± 0.59
    -0.94 ± 1.12
    -6.03 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 9 follow-up (n=8,13,1,0,0,0,0)
    -0.18 ± 1.04
    -0.29 ± 0.65
    -1.71 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 10 follow-up (n=1,5,0,0,0,0,0)
    0.1 ± 9999.999
    -0.93 ± 1.06
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    No statistical analyses for this end point

    Secondary: Change from baseline in triglycerides - Paediatric population

    		 Close Top of page
    End point title
    		 Change from baseline in triglycerides - Paediatric population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints. The number "9999.999" represents data not applicable for a particular arm.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Growth Hormone Deficiency (GHD) - Paediatric Population Small for Gestational Age (SGA) - Paediatric Population Turner Syndrome (TS) - Paediatric Population Chronic Renal Disease (CRD) - Paediatric Population Idiopathic Short Stature (ISS) - Paediatric Population Noonan Syndrome (NS) - Paediatric Population Prader-Willi Syndrome (PWS) - Paediatric Population
    Number of subjects analysed
    7141
    3200
    936
    200
    317
    106
    67
    Units: mmol/l
    arithmetic mean (standard deviation)
        Year 1 follow-up (n=267,114,44,8,17,6,0)
    0.18 ± 0.62
    0.09 ± 0.72
    0.12 ± 0.38
    0.64 ± 1.01
    -0.01 ± 0.55
    0.2 ± 0.24
    9999.999 ± 9999.999
        Year 2 follow-up (n=176,65,27,4,11,2,0)
    0.15 ± 0.65
    -0.07 ± 0.52
    0.06 ± 0.62
    -0.82 ± 1.36
    0.02 ± 0.56
    0.05 ± 0.64
    9999.999 ± 9999.999
        Year 3 follow-up (n=107,29,18,2,6,3,3)
    0.12 ± 0.77
    0.21 ± 0.65
    0.33 ± 0.62
    -0.03 ± 0.81
    -0.46 ± 0.52
    0.28 ± 0.28
    -0.15 ± 0.33
        Year 4 follow-up (n=67,35,14,1,1,1,0)
    0.29 ± 0.74
    0.11 ± 0.49
    0.17 ± 0.95
    1.31 ± 9999.999
    -0.04 ± 9999.999
    0 ± 9999.999
    9999.999 ± 9999.999
        Year 5 follow-up (n=37,24,6,1,1,0,0)
    0.29 ± 0.56
    0.18 ± 0.55
    0.13 ± 0.27
    1.22 ± 9999.999
    0.39 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 6 follow-up (n=30,18,4,1,0,0,0)
    0.31 ± 0.86
    0.01 ± 0.61
    0.1 ± 1.19
    0.5 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 7 follow-up (n=20,12,4,1,0,0,0)
    0.35 ± 0.62
    0.13 ± 0.58
    0.72 ± 1.32
    -3.73 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 8 follow-up (n=15,9,2,1,0,0,0)
    0.28 ± 0.56
    -0.04 ± 0.6
    0.93 ± 0.19
    -3.91 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 9 follow-up (n=8,4,1,0,0,0,0)
    0.21 ± 0.38
    -0.41 ± 0.48
    1.57 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
        Year 10 follow-up (n=1,0,0,0,0,0,0)
    0.38 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    No statistical analyses for this end point

    Secondary: Change from baseline in HbA1c - Adult population

    		 Close Top of page
    End point title
    		 Change from baseline in HbA1c - Adult population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Number of subjects analysed
    971
    Units: percentage of HbA1c
    arithmetic mean (standard deviation)
        Female: Year 1 follow-up (n=141)
    -0.03 ± 0.48
        Female: Year 2 follow-up (n=104)
    0.03 ± 0.5
        Female: Year 3 follow-up (n=73)
    -0.05 ± 0.71
        Female: Year 4 follow-up (n=64)
    0.13 ± 0.86
        Female: Year 5 follow-up (n=55)
    0.18 ± 0.76
        Female: Year 6 follow-up (n=46)
    0.09 ± 0.7
        Female: Year 7 follow-up (n=33)
    0.12 ± 0.68
        Female: Year 8 follow-up (n=26)
    0.1 ± 0.76
        Female: Year 9 follow-up (n=18)
    0.03 ± 0.42
        Female: Year 10 follow-up (n=19)
    0.02 ± 1
        Male: Year 1 follow-up (n=155)
    0.01 ± 0.43
        Male: Year 2 follow-up (n=140)
    -0.04 ± 0.55
        Male: Year 3 follow-up (n=100)
    0.08 ± 0.37
        Male: Year 4 follow-up (n=83)
    0.1 ± 0.7
        Male: Year 5 follow-up (n=63)
    0.05 ± 0.53
        Male: Year 6 follow-up (n=56)
    0.12 ± 0.4
        Male: Year 7 follow-up (n=48)
    -0.03 ± 0.5
        Male: Year 8 follow-up (n=40)
    0.13 ± 0.74
        Male: Year 9 follow-up (n=22)
    0.23 ± 0.64
        Male: Year 10 follow-up (n=13)
    -0.01 ± 0.65
    No statistical analyses for this end point

    Secondary: Change from baseline in fasting blood glucose - Adult population

    		 Close Top of page
    End point title
    		 Change from baseline in fasting blood glucose - Adult population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Number of subjects analysed
    971
    Units: mmol/l
    arithmetic mean (standard deviation)
        Female: Year 1 follow-up (n=102)
    0.16 ± 1.19
        Female: Year 2 follow-up (n=71)
    0.28 ± 1.76
        Female: Year 3 follow-up (n=58)
    0.4 ± 0.83
        Female: Year 4 follow-up (n=49)
    1.22 ± 4.99
        Female: Year 5 follow-up (n=38)
    0.24 ± 0.82
        Female: Year 6 follow-up (n=28)
    0.42 ± 1.02
        Female: Year 7 follow-up (n=23)
    0.15 ± 1.86
        Female: Year 8 follow-up (n=16)
    0.52 ± 0.96
        Female: Year 9 follow-up (n=15)
    0.27 ± 0.82
        Female: Year 10 follow-up (n=11)
    -0.34 ± 2.91
        Male: Year 1 follow-up (n=121)
    0.23 ± 1.15
        Male: Year 2 follow-up (n=90)
    0.21 ± 0.86
        Male: Year 3 follow-up (n=71)
    0.18 ± 0.76
        Male: Year 4 follow-up (n=61)
    0.21 ± 1.06
        Male: Year 5 follow-up (n=43)
    0.47 ± 0.86
        Male: Year 6 follow-up (n=38)
    0.6 ± 1.21
        Male: Year 7 follow-up (n=31)
    0.55 ± 0.85
        Male: Year 8 follow-up (n=29)
    0.84 ± 2.48
        Male: Year 9 follow-up (n=17)
    0.26 ± 1.4
        Male: Year 10 follow-up (n=18)
    1.22 ± 2.9
    No statistical analyses for this end point

    Secondary: Change from baseline in total cholesterol - Adult population

    		 Close Top of page
    End point title
    		 Change from baseline in total cholesterol - Adult population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Number of subjects analysed
    971
    Units: mmol/l
    arithmetic mean (standard deviation)
        Female: Year 1 follow-up (n=132)
    0.03 ± 0.88
        Female: Year 2 follow-up (n=103)
    -0.06 ± 1.09
        Female: Year 3 follow-up (n=79)
    -0.07 ± 1.24
        Female: Year 4 follow-up (n=64)
    -0.16 ± 1.07
        Female: Year 5 follow-up (n=58)
    -0.19 ± 1.15
        Female: Year 6 follow-up (n=48)
    -0.2 ± 0.93
        Female: Year 7 follow-up (n=36)
    -0.53 ± 1.46
        Female: Year 8 follow-up (n=27)
    -0.46 ± 1.29
        Female: Year 9 follow-up (n=30)
    -0.43 ± 1.58
        Female: Year 10 follow-up (n=18)
    -0.52 ± 1.63
        Male: Year 1 follow-up (n=160)
    -0.25 ± 0.94
        Male: Year 2 follow-up (n=144)
    -0.44 ± 1.01
        Male: Year 3 follow-up (n=106)
    -0.37 ± 1.24
        Male: Year 4 follow-up (n=87)
    -0.39 ± 1.15
        Male: Year 5 follow-up (n=72)
    -0.24 ± 1.02
        Male: Year 6 follow-up (n=62)
    -0.51 ± 1.05
        Male: Year 7 follow-up (n=51)
    -0.72 ± 1.27
        Male: Year 8 follow-up (n=40)
    -0.74 ± 1.3
        Male: Year 9 follow-up (n=33)
    -1.02 ± 1.08
        Male: Year 10 follow-up (n=25)
    -0.87 ± 1.39
    No statistical analyses for this end point

    Secondary: Change from baseline in HDL cholesterol - Adult population

    		 Close Top of page
    End point title
    		 Change from baseline in HDL cholesterol - Adult population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Number of subjects analysed
    971
    Units: mmol/l
    arithmetic mean (standard deviation)
        Female: Year 1 follow-up (n=127)
    0.03 ± 0.41
        Female: Year 2 follow-up (n=98)
    -0.01 ± 0.33
        Female: Year 3 follow-up (n=79)
    0.03 ± 0.46
        Female: Year 4 follow-up (n=65)
    0.03 ± 0.4
        Female: Year 5 follow-up (n=57)
    0.05 ± 0.4
        Female: Year 6 follow-up (n=46)
    -0.06 ± 0.44
        Female: Year 7 follow-up (n=33)
    -0.04 ± 0.5
        Female: Year 8 follow-up (n=24)
    0.04 ± 0.41
        Female: Year 9 follow-up (n=27)
    0.03 ± 0.33
        Female: Year 10 follow-up (n=18)
    0.06 ± 0.27
        Male: Year 1 follow-up (n=160)
    -0.02 ± 0.23
        Male: Year 2 follow-up (n=139)
    -0 ± 0.28
        Male: Year 3 follow-up (n=101)
    0 ± 0.21
        Male: Year 4 follow-up (n=81)
    0.04 ± 0.28
        Male: Year 5 follow-up (n=67)
    0.07 ± 0.21
        Male: Year 6 follow-up (n=54)
    0.08 ± 0.46
        Male: Year 7 follow-up (n=50)
    0.18 ± 0.52
        Male: Year 8 follow-up (n=34)
    0.12 ± 0.43
        Male: Year 9 follow-up (n=31)
    0.14 ± 0.35
        Male: Year 10 follow-up (n=23)
    0.1 ± 0.2
    No statistical analyses for this end point

    Secondary: Change from baseline in LDL cholesterol - Adult population

    		 Close Top of page
    End point title
    		 Change from baseline in LDL cholesterol - Adult population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Number of subjects analysed
    971
    Units: mmol/l
    arithmetic mean (standard deviation)
        Female: Year 1 follow-up (n=104)
    -0.04 ± 0.9
        Female: Year 2 follow-up (n=74)
    -0.08 ± 1.06
        Female: Year 3 follow-up (n=54)
    -0.01 ± 1.34
        Female: Year 4 follow-up (n=46)
    -0.08 ± 0.86
        Female: Year 5 follow-up (n=43)
    0.05 ± 1.06
        Female: Year 6 follow-up (n=36)
    -0.11 ± 1.19
        Female: Year 7 follow-up (n=24)
    -0.33 ± 1.4
        Female: Year 8 follow-up (n=15)
    0 ± 1.59
        Female: Year 9 follow-up (n=17)
    -0.31 ± 1.48
        Female: Year 10 follow-up (n=9)
    -0.05 ± 1.68
        Male: Year 1 follow-up (n=120)
    -0.28 ± 0.85
        Male: Year 2 follow-up (n=106)
    -0.42 ± 0.85
        Male: Year 3 follow-up (n=70)
    -0.42 ± 0.9
        Male: Year 4 follow-up (n=51)
    -0.37 ± 0.9
        Male: Year 5 follow-up (n=47)
    -0.19 ± 0.82
        Male: Year 6 follow-up (n=37)
    -0.45 ± 0.98
        Male: Year 7 follow-up (n=31)
    -0.34 ± 0.97
        Male: Year 8 follow-up (n=21)
    -0.53 ± 0.74
        Male: Year 9 follow-up (n=18)
    -0.61 ± 0.84
        Male: Year 10 follow-up (n=9)
    -0.63 ± 0.73
    No statistical analyses for this end point

    Secondary: Change from baseline in triglycerides - Adult population

    		 Close Top of page
    End point title
    		 Change from baseline in triglycerides - Adult population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints. The number "9999.999" represents data not applicable for a particular arm.
    End point type
    Secondary
    End point timeframe
    Up to 9 years of follow up
    End point values
    		 Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Number of subjects analysed
    971
    Units: mmol/l
    arithmetic mean (standard deviation)
        Female: Year 1 follow-up (n=35)
    0.17 ± 1
        Female: Year 2 follow-up (n=18)
    0.04 ± 0.7
        Female: Year 3 follow-up (n=10)
    -0.02 ± 0.66
        Female: Year 4 follow-up (n=10)
    0.2 ± 1.05
        Female: Year 5 follow-up (n=10)
    -0.06 ± 0.93
        Female: Year 6 follow-up (n=9)
    0.09 ± 0.7
        Female: Year 7 follow-up (n=3)
    0.48 ± 2.63
        Female: Year 8 follow-up (n=1)
    1.06 ± 9999.999
        Male: Year 1 follow-up (n=50)
    0.2 ± 0.78
        Male: Year 2 follow-up (n=40)
    0.19 ± 0.74
        Male: Year 3 follow-up (n=16)
    0.02 ± 0.38
        Male: Year 4 follow-up (n=11)
    -0.05 ± 0.6
        Male: Year 5 follow-up (n=9)
    -0.17 ± 0.67
        Male: Year 6 follow-up (n=6)
    -0.41 ± 0.99
        Male: Year 7 follow-up (n=5)
    -0.17 ± 0.74
        Male: Year 9 follow-up (n=1)
    1.7 ± 9999.999
    No statistical analyses for this end point

    Secondary: Change from baseline in Bone age/Chronological age - Paediatric population

    		 Close Top of page
    End point title
    		 Change from baseline in Bone age/Chronological age - Paediatric population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints. The number "9999.999" represents data not applicable for a particular arm
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Growth Hormone Deficiency (GHD) - Paediatric Population Small for Gestational Age (SGA) - Paediatric Population Turner Syndrome (TS) - Paediatric Population Chronic Renal Disease (CRD) - Paediatric Population Idiopathic Short Stature (ISS) - Paediatric Population Noonan Syndrome (NS) - Paediatric Population Prader-Willi Syndrome (PWS) - Paediatric Population
    Number of subjects analysed
    7141
    3200
    936
    200
    317
    106
    67
    Units: ratio
    arithmetic mean (standard deviation)
        Year 1 follow-up (n=1250,602,199,31,39,11,3)
    0.04 ± 0.12
    0.05 ± 0.13
    0.02 ± 0.14
    0.04 ± 0.09
    0.02 ± 0.1
    0.01 ± 0.09
    0.1 ± 0.15
        Year 2 follow-up (n=975,475,164,16,32,12,4)
    0.09 ± 0.14
    0.09 ± 0.15
    0.07 ± 0.15
    0.12 ± 0.17
    0.05 ± 0.12
    0.09 ± 0.13
    0.11 ± 0.32
        Year 3 follow-up (n=774,364,146,14,19,7,3)
    0.13 ± 0.15
    0.15 ± 0.17
    0.07 ± 0.15
    0.1 ± 0.12
    0.07 ± 0.14
    0.13 ± 0.15
    0.08 ± 0.28
        Year 4 follow-up (n=518,265,116,8,14,3,5)
    0.17 ± 0.17
    0.18 ± 0.17
    0.1 ± 0.17
    0.18 ± 0.2
    0.03 ± 0.16
    0.16 ± 0.14
    0.21 ± 0.33
        Year 5 follow-up (n=406,194,87,6,11,5,5)
    0.21 ± 0.18
    0.21 ± 0.18
    0.13 ± 0.18
    0.1 ± 0.26
    0.14 ± 0.13
    0.23 ± 0.17
    0.28 ± 0.39
        Year 6 follow-up (n=244,138,55,4,2,2,1)
    0.25 ± 0.33
    0.24 ± 0.18
    0.15 ± 0.19
    0.17 ± 0.45
    0.25 ± 0.11
    0.13 ± 0.05
    0.25 ± 9999.999
        Year 7 follow-up (n=172,109,48,3,3,0,1)
    0.27 ± 0.37
    0.25 ± 0.23
    0.16 ± 0.19
    0.34 ± 0.18
    0.22 ± 0.09
    9999.999 ± 9999.999
    0.15 ± 9999.999
        Year 8 follow-up (n=123,66,31,0,3,1,2)
    0.28 ± 0.42
    0.32 ± 0.18
    0.2 ± 0.17
    9999.999 ± 9999.999
    0.04 ± 0.08
    0.03 ± 9999.999
    0.29 ± 0.05
        Year 9 follow-up (n=82,45,15,1,3,2,2)
    0.25 ± 0.5
    0.3 ± 0.26
    0.17 ± 0.19
    0.23 ± 9999.999
    0.24 ± 0.13
    0.09 ± 0.12
    0.26 ± 0
        Year 10 follow-up (n=29,14,10,1,1,0,1)
    0.21 ± 0.8
    0.35 ± 0.22
    0.13 ± 0.34
    0.38 ± 9999.999
    0.18 ± 9999.999
    9999.999 ± 9999.999
    0.27 ± 9999.999
    No statistical analyses for this end point

    Secondary: Change from baseline in insulin-like growth factor 1 (IGF-I) SDS (Brabant) - Paediatric population

    		 Close Top of page
    End point title
    		 Change from baseline in insulin-like growth factor 1 (IGF-I) SDS (Brabant) - Paediatric population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints. The number "9999.999" represents data not applicable for a particular arm
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Growth Hormone Deficiency (GHD) - Paediatric Population Small for Gestational Age (SGA) - Paediatric Population Turner Syndrome (TS) - Paediatric Population Chronic Renal Disease (CRD) - Paediatric Population Idiopathic Short Stature (ISS) - Paediatric Population Noonan Syndrome (NS) - Paediatric Population Prader-Willi Syndrome (PWS) - Paediatric Population
    Number of subjects analysed
    7141
    3200
    936
    200
    317
    106
    67
    Units: Standard deviation scores
    arithmetic mean (standard deviation)
        Year 1 follow-up (n=2562,1044,314,30,93,20,16)
    2.17 ± 1.62
    1.73 ± 1.41
    2.26 ± 1.45
    2.03 ± 1.69
    1.8 ± 1.57
    1.53 ± 1.3
    1.71 ± 1.85
        Year 2 follow-up (n=2092,826,252,17,67,20,14)
    2.42 ± 1.81
    1.78 ± 1.54
    2.28 ± 1.69
    2.32 ± 2.27
    2.18 ± 1.72
    1.79 ± 1.52
    2.1 ± 1.52
        Year 3 follow-up (n=1673,652,235,19,47,11,11)
    2.45 ± 1.88
    1.83 ± 1.59
    2.37 ± 1.76
    2.47 ± 2.03
    2.41 ± 1.95
    1.58 ± 2.23
    1.91 ± 1.78
        Year 4 follow-up (n=1248,502,176,9,31,10,11)
    2.25 ± 1.9
    1.68 ± 1.7
    2.1 ± 1.81
    2.84 ± 1.82
    2.04 ± 2.09
    1.6 ± 1.91
    2.1 ± 1.69
        Year 5 follow-up (n=881,361,139,7,19,5,7)
    2.18 ± 1.92
    1.36 ± 1.9
    1.86 ± 2.1
    1.42 ± 2.12
    2.09 ± 1.75
    0.65 ± 2.15
    1.65 ± 1.94
        Year 6 follow-up (n=634,267,96,5,10,4,3)
    1.95 ± 1.93
    1.39 ± 1.76
    1.71 ± 1.69
    2.36 ± 0.99
    1.12 ± 2.18
    0.99 ± 2.84
    0.52 ± 2.69
        Year 7 follow-up (n=428,188,73,4,9,3,2)
    1.91 ± 1.8
    1.54 ± 1.68
    1.71 ± 1.83
    1.31 ± 1.22
    1.81 ± 1.45
    -2.07 ± 1.31
    -0.32 ± 2.59
        Year 8 follow-up (n=285,117,44,2,5,3,1)
    1.68 ± 2.01
    1.37 ± 1.69
    1.5 ± 1.83
    1.04 ± 1.73
    2.68 ± 2.11
    -0.81 ± 1.03
    -0.45 ± 9999.999
        Year 9 follow-up (n=204,83,29,3,1,3,2)
    1.67 ± 1.78
    1.44 ± 1.76
    1.75 ± 1.4
    2.38 ± 2.27
    3.13 ± 9999.999
    -1.35 ± 1.82
    -0.98 ± 3.47
        Year 10 follow-up (n=108,39,16,3,1,1,2)
    1.72 ± 1.8
    1.23 ± 1.53
    1.83 ± 1.47
    2.03 ± 0.54
    4.16 ± 9999.999
    -1.27 ± 9999.999
    -0.81 ± 4.01
    No statistical analyses for this end point

    Secondary: Change from baseline in insulin-like growth factor binding protein 3 (IGFBP-3) SDS (Juul) - Paediatric population

    		 Close Top of page
    End point title
    		 Change from baseline in insulin-like growth factor binding protein 3 (IGFBP-3) SDS (Juul) - Paediatric population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints. The number "9999.999" represents data not applicable for a particular arm
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Growth Hormone Deficiency (GHD) - Paediatric Population Small for Gestational Age (SGA) - Paediatric Population Turner Syndrome (TS) - Paediatric Population Chronic Renal Disease (CRD) - Paediatric Population Idiopathic Short Stature (ISS) - Paediatric Population Noonan Syndrome (NS) - Paediatric Population Prader-Willi Syndrome (PWS) - Paediatric Population
    Number of subjects analysed
    7141
    3200
    936
    200
    317
    106
    67
    Units: Standard deviation scores
    arithmetic mean (standard deviation)
        Year 1 follow-up (n=1386,589,145,18,45,11,9)
    1.4 ± 1.7
    1.33 ± 1.5
    1.43 ± 1.74
    2.04 ± 1.77
    1.3 ± 2.19
    1.01 ± 1.42
    2.16 ± 1.24
        Year 2 follow-up (n=1126,453,119,8,30,7,8)
    1.63 ± 1.79
    1.47 ± 1.65
    1.79 ± 1.82
    2.23 ± 1.63
    1.94 ± 1.21
    1.28 ± 1.14
    1.69 ± 1.4
        Year 3 follow-up (n=893,359,117,9,18,5,7)
    1.82 ± 1.92
    1.65 ± 1.73
    2.02 ± 1.89
    2.87 ± 3.34
    1.88 ± 1.53
    2.39 ± 2.78
    2.37 ± 2.29
        Year 4 follow-up (n=670,283,80,3,15,2,5)
    1.92 ± 1.98
    1.75 ± 1.9
    1.85 ± 2.34
    2.31 ± 2.16
    1.45 ± 1.3
    1.22 ± 0.91
    2.83 ± 1.4
        Year 5 follow-up (n=488,204,66,2,9,2,4)
    2.01 ± 1.95
    1.85 ± 2.06
    1.51 ± 2.31
    2.41 ± 0.12
    1.91 ± 1.51
    1.34 ± 0.81
    3 ± 2.83
        Year 6 follow-up (n=339,160,44,2,5,1,1)
    2.05 ± 2.11
    2.21 ± 1.97
    2 ± 2.01
    2.32 ± 1.53
    1.16 ± 1.8
    0.32 ± 9999.999
    3.08 ± 9999.999
        Year 7 follow-up (n=210,113,32,3,6,1,0)
    2.3 ± 2.16
    2.26 ± 2.18
    1.98 ± 2.09
    2.43 ± 1.67
    2.27 ± 3.01
    0.29 ± 9999.999
    9999.999 ± 9999.999
        Year 8 follow-up (n=140,75,19,2,2,1,0)
    1.79 ± 2.22
    2.1 ± 1.96
    1.86 ± 2.62
    1.98 ± 1.63
    1.08 ± 1.94
    0.59 ± 9999.999
    9999.999 ± 9999.999
        Year 9 follow-up (n=91,57,12,1,0,1,0)
    2.2 ± 2.19
    2.08 ± 2.03
    1.8 ± 1.96
    3.15 ± 9999.999
    9999.999 ± 9999.999
    0.28 ± 9999.999
    9999.999 ± 9999.999
        Year 10 follow-up (n=44,28,5,2,0,0,0)
    2.43 ± 2.15
    2.1 ± 1.64
    2.69 ± 1.28
    3.14 ± 1.16
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    9999.999 ± 9999.999
    No statistical analyses for this end point

    Secondary: Change from baseline in BMI - Adult population

    		 Close Top of page
    End point title
    		 Change from baseline in BMI - Adult population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Number of subjects analysed
    971
    Units: kg/sqm
    arithmetic mean (standard deviation)
        Female: Year 1 follow-up (n=268)
    -0.04 ± 3.02
        Female: Year 2 follow-up (n=206)
    0.57 ± 4.89
        Female: Year 3 follow-up (n=166)
    0.6 ± 4.29
        Female: Year 4 follow-up (n=134)
    0.46 ± 2.92
        Female: Year 5 follow-up (n=112)
    0.23 ± 2.72
        Female: Year 6 follow-up (n=95)
    0.18 ± 2.66
        Female: Year 7 follow-up (n=82)
    0.27 ± 3.17
        Female: Year 8 follow-up (n=62)
    0.8 ± 2.9
        Female: Year 9 follow-up (n=56)
    0.4 ± 3.1
        Female: Year 10 follow-up (n=39)
    0.82 ± 3.11
        Male: Year 1 follow-up (n=310)
    0.18 ± 3.21
        Male: Year 2 follow-up (n=262)
    0 ± 2.52
        Male: Year 3 follow-up (n=193)
    0.41 ± 4.53
        Male: Year 4 follow-up (n=177)
    0.31 ± 3.64
        Male: Year 5 follow-up (n=139)
    0.31 ± 3.38
        Male: Year 6 follow-up (n=120)
    0.52 ± 2.95
        Male: Year 7 follow-up (n=94)
    0.32 ± 3.48
        Male: Year 8 follow-up (n=88)
    0.68 ± 3.51
        Male: Year 9 follow-up (n=63)
    0.66 ± 3.53
        Male: Year 10 follow-up (n=50)
    1.07 ± 3.04
    No statistical analyses for this end point

    Secondary: Change from baseline in IGF-I SDS (Brabant) - Adult population

    		 Close Top of page
    End point title
    		 Change from baseline in IGF-I SDS (Brabant) - Adult population
    End point description
    Analysis was based on the effectiveness analysis set. Here, "n" represents the number of subjects with data available at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Up to 10 years of follow up
    End point values
    		 Adult Growth Hormone Deficiency (AGHD) - Adult Population
    Number of subjects analysed
    971
    Units: Standard deviation scores
    arithmetic mean (standard deviation)
        Female: Year 1 follow-up (n=219)
    1.2 ± 1.51
        Female: Year 2 follow-up (n=168)
    1.32 ± 1.47
        Female: Year 3 follow-up (n=133)
    1.29 ± 1.4
        Female: Year 4 follow-up (n=112)
    1.52 ± 1.45
        Female: Year 5 follow-up (n=90)
    1.27 ± 1.43
        Female: Year 6 follow-up (n=69)
    1.47 ± 1.56
        Female: Year 7 follow-up (n=62)
    1.8 ± 1.17
        Female: Year 8 follow-up (n=47)
    1.54 ± 1.46
        Female: Year 9 follow-up (n=41)
    1.93 ± 1.44
        Female: Year 10 follow-up (n=27)
    1.46 ± 1.49
        Male: Year 1 follow-up (n=258)
    1.52 ± 1.47
        Male: Year 2 follow-up (n=218)
    1.64 ± 1.46
        Male: Year 3 follow-up (n=167)
    1.51 ± 1.52
        Male: Year 4 follow-up (n=149)
    1.42 ± 1.47
        Male: Year 5 follow-up (n=107)
    1.41 ± 1.55
        Male: Year 6 follow-up (n=97)
    1.54 ± 1.53
        Male: Year 7 follow-up (n=82)
    1.34 ± 1.43
        Male: Year 8 follow-up (n=71)
    1.03 ± 1.49
        Male: Year 9 follow-up (n=54)
    1.48 ± 1.45
        Male: Year 10 follow-up (n=46)
    1.72 ± 1.29
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information [1]
    Timeframe for reporting adverse events
    Full study duration (01 Apr 2006 to 31 Dec 2016)
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    20
    Reporting groups
    Reporting group title
    Paediatric GHD
    Reporting group description
    		 Paediatric patients with Growth Hormone Deficiency who were being treated with Norditropin®. The population represents full analysis set.

    Reporting group title
    Paediatric SGA
    Reporting group description
    		 Paediatric patients with Small for Gestational Age (SGA) who were being treated with Norditropin®. The population represents full analysis set.

    Reporting group title
    Paediatric TS
    Reporting group description
    		 Paediatric patients with Turner Syndrome (TA) who were being treated with Norditropin®. The population represents full analysis set.

    Reporting group title
    Paediatric CRD
    Reporting group description
    		 Paediatric patients with chronic renal disease (CRD) who were being treated with Norditropin®. The population represents full analysis set.

    Reporting group title
    Paediatric ISS
    Reporting group description
    		 Paediatric patients with idiopathic short stature (ISS) who were being treated with Norditropin®. The population represents full analysis set.

    Reporting group title
    Paediatric NS
    Reporting group description
    		 Paediatric patients with Noonan syndrome (NS) who were being treated with Norditropin®. The population represents full analysis set.

    Reporting group title
    Paediatric PWS
    Reporting group description
    		 Paediatric patients with Prader-Willi Syndrome (PWS) who were being treated with Norditropin®. The population represents full analysis set.

    Reporting group title
    Paediatric Other
    Reporting group description
    		 The paediatric population with other growth disorder. The population represents full analysis set.

    Reporting group title
    Adult GHD
    Reporting group description
    		 Adult patients with adult growth hormone disease (GHD) who were being treated with Norditropin®. The population represents full analysis set.

    Reporting group title
    Adult Other
    Reporting group description
    		 -

    Notes
    [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
    Justification: There were no non-serious adverse events with frequency of more than 5% in any sub-group.
    Serious adverse events
    		 Paediatric GHD Paediatric SGA Paediatric TS Paediatric CRD Paediatric ISS Paediatric NS Paediatric PWS Paediatric Other Adult GHD Adult Other
    Total subjects affected by serious adverse events
         subjects affected / exposed
    174 / 9996 (1.74%)
    51 / 4274 (1.19%)
    30 / 1374 (2.18%)
    7 / 290 (2.41%)
    9 / 485 (1.86%)
    3 / 154 (1.95%)
    11 / 132 (8.33%)
    18 / 1035 (1.74%)
    133 / 2321 (5.73%)
    10 / 163 (6.13%)
         number of deaths (all causes)
    4
    1
    0
    2
    0
    0
    1
    3
    14
    0
         number of deaths resulting from adverse events
    1
    0
    0
    1
    0
    0
    0
    0
    2
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Acute myeloid leukaemia
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Adenoma benign
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anaplastic astrocytoma
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    Angiosarcoma metastatic
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    1 / 1374 (0.07%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Astrocytoma malignant
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Benign neoplasm
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bladder neoplasm
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Brain neoplasm
         subjects affected / exposed
    3 / 9996 (0.03%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchial carcinoma
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Burkitt's lymphoma
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Choroid plexus carcinoma
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colon cancer metastatic
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    Craniopharyngioma
         subjects affected / exposed
    3 / 9996 (0.03%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Craniopharyngioma benign
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enchondromatosis
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Follicle centre lymphoma, follicular grade I, II, III
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastric cancer stage 0
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Glioma
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    1 / 1035 (0.10%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Glioneuronal tumour
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    1 / 154 (0.65%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemangioma
         subjects affected / exposed
    2 / 9996 (0.02%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hodgkin's disease
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intraductal papillary mucinous neoplasm
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lipoma
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung adenocarcinoma
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymphocytic leukaemia
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Malignant melanoma
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    1 / 163 (0.61%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Mantle cell lymphoma
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Medulloblastoma recurrent
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    1 / 1035 (0.10%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Metastases to meninges
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metastases to spine
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Multiple myeloma
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myelofibrosis
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nasal sinus cancer
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neoplasm
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neoplasm malignant
         subjects affected / exposed
    3 / 9996 (0.03%)
    0 / 4274 (0.00%)
    1 / 1374 (0.07%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    9 / 2321 (0.39%)
    1 / 163 (0.61%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    4 / 11
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    Neoplasm progression
         subjects affected / exposed
    3 / 9996 (0.03%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    1 / 1035 (0.10%)
    3 / 2321 (0.13%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    2 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    1 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neoplasm recurrence
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    2 / 1035 (0.19%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Nephroblastoma
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Non-secretory adenoma of pituitary
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    2 / 2321 (0.09%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    2 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oral neoplasm benign
         subjects affected / exposed
    0 / 9996 (0.00%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Papillary renal cell carcinoma
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Papillary thyroid cancer
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pituitary tumour
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    3 / 2321 (0.13%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pituitary tumour benign
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    3 / 2321 (0.13%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    2 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Primitive neuroectodermal tumour
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    1 / 485 (0.21%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    2 / 1035 (0.19%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Prostate cancer
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Recurrent cancer
         subjects affected / exposed
    2 / 9996 (0.02%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal cancer
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal cell carcinoma
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Schwannoma
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    T-cell lymphoma
         subjects affected / exposed
    0 / 9996 (0.00%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Deep vein thrombosis
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    1 / 163 (0.61%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhage
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    1 / 1035 (0.10%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Hypertension
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    1 / 1374 (0.07%)
    1 / 290 (0.34%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypotension
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Shock
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Venous thrombosis
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Venous thrombosis limb
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Surgical and medical procedures
    Adenoidectomy
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Adenotonsillectomy
         subjects affected / exposed
    0 / 9996 (0.00%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    1 / 1035 (0.10%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bone lesion excision
         subjects affected / exposed
    0 / 9996 (0.00%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystectomy
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    2 / 2321 (0.09%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystostomy
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ear operation
         subjects affected / exposed
    0 / 9996 (0.00%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrostomy closure
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    1 / 290 (0.34%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hip surgery
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hospitalisation
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Limb operation
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myringotomy
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Orchidopexy
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peritoneal dialysis
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    1 / 290 (0.34%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pituitary tumour removal
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Plastic surgery to the face
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal transplant
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    1 / 290 (0.34%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    1 / 1035 (0.10%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rotator cuff repair
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal fusion surgery
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    1 / 154 (0.65%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Strabismus correction
         subjects affected / exposed
    0 / 9996 (0.00%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ventricular septal defect repair
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wisdom teeth removal
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pregnancy, puerperium and perinatal conditions
    Pre-eclampsia
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chest pain
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    2 / 2321 (0.09%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Condition aggravated
         subjects affected / exposed
    2 / 9996 (0.02%)
    2 / 4274 (0.05%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    1 / 154 (0.65%)
    2 / 132 (1.52%)
    1 / 1035 (0.10%)
    3 / 2321 (0.13%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 2
    0 / 1
    1 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Death
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    4 / 2321 (0.17%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 4
    0 / 0
    Discomfort
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Disease recurrence
         subjects affected / exposed
    3 / 9996 (0.03%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Face oedema
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    1 / 290 (0.34%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fatigue
         subjects affected / exposed
    2 / 9996 (0.02%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperthermia
         subjects affected / exposed
    2 / 9996 (0.02%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injection site atrophy
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Malaise
         subjects affected / exposed
    2 / 9996 (0.02%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oedema
         subjects affected / exposed
    2 / 9996 (0.02%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peripheral swelling
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    3 / 9996 (0.03%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sudden death
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    1 / 132 (0.76%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Ovarian cyst
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ovarian disorder
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    1 / 1374 (0.07%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Varicocele
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Adenoidal disorder
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    1 / 1374 (0.07%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asthma
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    1 / 132 (0.76%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dysphonia
         subjects affected / exposed
    0 / 9996 (0.00%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dyspnoea
         subjects affected / exposed
    0 / 9996 (0.00%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperventilation
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung disorder
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    1 / 1374 (0.07%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oropharyngeal pain
         subjects affected / exposed
    0 / 9996 (0.00%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumothorax
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary artery wall hypertrophy
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary oedema
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    1 / 290 (0.34%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rhinorrhoea
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sleep apnoea syndrome
         subjects affected / exposed
    0 / 9996 (0.00%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    1 / 132 (0.76%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stridor
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tonsillar hypertrophy
         subjects affected / exposed
    0 / 9996 (0.00%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Completed suicide
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Depression
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    3 / 2321 (0.13%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mental disorder
         subjects affected / exposed
    1 / 9996 (0.01%)
    1 / 4274 (0.02%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Restlessness
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Screaming
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sleep disorder
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stress
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Suicide attempt
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    1 / 2321 (0.04%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tic
         subjects affected / exposed
    1 / 9996 (0.01%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    0 / 485 (0.00%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 / 163 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Product issues
    Device malfunction
    alternative dictionary used: MedDRA 3
         subjects affected / exposed
    0 / 9996 (0.00%)
    0 / 4274 (0.00%)
    0 / 1374 (0.00%)
    0 / 290 (0.00%)
    1 / 485 (0.21%)
    0 / 154 (0.00%)
    0 / 132 (0.00%)
    0 / 1035 (0.00%)
    0 / 2321 (0.00%)
    0 /